IMBdx Q1 2026 Revenue up 27% QoQ, Losses Continue
아이엠비디엑스
461030
Signal Score
Historical Avg Return (5d)
-0.18%
Data Coverage
100%n=3385
Risk-adjusted indicator based on 3385 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Q1 2026 Revenue: 1.27B KRW
- • Q1 2026 Operating Loss: 2.46B KRW
- • Q1 2026 Net Loss: 2.25B KRW
- • Q1 2026 Basic EPS: -159 KRW
- • Q1 2026 Revenue (QoQ): +27.05%
- • Q1 2026 Overseas Revenue (QoQ): +86.45%
AI Analysis Summary
IMBdx, Inc. reported its Q1 2026 financial results, showing a revenue of 1.27 billion KRW, a 27.05% increase from the previous quarter (Q4 2025). Despite the revenue growth, the company recorded an operating loss of 2.46 billion KRW and a net loss of 2.25 billion KRW. Basic EPS was -159 KRW. Overseas revenue saw significant growth, increasing by 86.45% QoQ to 668.94 million KRW, driven by expansion in Taiwan, Malaysia, Vietnam, and new markets like Japan and India. The company continues to invest heavily in R&D, with 33 ongoing projects, including expanding its CancerFind product to 15 cancer types by 2026. While revenue growth, especially internationally, is positive, the company remains unprofitable, indicating continued investment in market penetration and R&D.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.